SciDev.Net

As tuberculosis strains that are resistant to all known drugs continue to emerge, scientists are trying new approaches to drug development.

Polio is still with us, and scientists are having to rethink vaccination strategies for developing countries in the hope of eradication.

Developing countries are attractive places to run clinical trials, but in many places ethical oversight falls short.

Big pharma drug companies are striking deals with Asian drug researchers to secure the future of the drug industry.

Trials of a vaccine to prevent nasopharyngeal cancer will start soon in China, where it mainly affects the Cantonese-speaking population.

Vaccines for non-infectious illness could help developing nations tackle the growing burden of chronic disease. Maryke Steffens reports.

Priya Shetty explores the truths and the myths about chronic diseases in the developing world.

Leading geneticist Samir Brahmachari explains why India should kickstart a new open source approach to drug discovery for diseases like TB.

Traditional healers are joining forces with plant chemists in Kenya to develop antimalarials isolated from plants, reports Tatum Anderson.

The debate goes on over China's ongoing production of malaria monotherapy, which is thought to promote drug resistance. Jane Wu reports.

By setting up a comprehensive R&D centre in China, Swiss drug giant Novartis breaks a longstanding trend. Richard Stone and Hao Xin report.

An ambitious 15-year plan could make China a scientific heavyweight, or could prove too big to handle, report Hao Xin and Gong Yidong.